Beijing Leadman Biochemistry Co Ltd
Beijing Leadman Biochemistry Co Ltd is a medical equipment and supplies company operating in the healthcare services and equipment sector.
Business. Beijing Leadman Biochemistry Co Ltd (300289.SZ) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm is headquartered in Beijing and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Beijing Leadman Biochemistry Co Ltd (300289.SZ) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm is headquartered in Beijing and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
The company's capital structure is characterized by a very low debt-to-equity ratio of 0.0, indicating a nearly debt-free balance sheet. Total equity of 1.64 billion CNY supports total assets of 1.78 billion CNY, with a current ratio of 12.71, suggesting strong short-term liquidity. However, the company reported negative operating income of 17.85 million CNY and a net loss of 22.98 million CNY, indicating operational challenges. Free cash flow is minimal at 817,250 CNY, and capital expenditures of 17.59 million CNY suggest ongoing investment in operations.
Profitability metrics are weak, with a return on equity of -1.4% and a return on assets of -1.29%, both significantly below the industry median for medical equipment and supplies firms. Gross profit of 151.18 million CNY on revenue of 326.31 million CNY implies a gross margin of 46.3%, which is in line with industry norms but insufficient to offset operating costs.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of segment and geographic diversification increases exposure to sector-specific risks.
Looking ahead, the company's revenue outlook is uncertain, with a reported net loss and negative operating income in the most recent period. Analyst estimates suggest a revenue of 654.80 million CNY, but this is not yet reflected in the company's financial performance. The company's capital expenditures and operating cash flow suggest it is maintaining operations but not growing at a significant pace.
The risk assessment highlights medium liquidity risk due to negative net cash after subtracting total debt, despite the company's low leverage. Dilution risk is assessed as low, with no near-term pressure from share issuance or dilutive events. The company's financial structure and performance suggest a need for operational improvements to restore profitability.
Recent filings and transcripts do not provide additional insight into the company's strategic direction or operational changes. The company's performance remains a concern, with no clear path to profitability in the near term.
- The company is nearly debt-free but is reporting a net loss and negative operating income.
- Liquidity is strong, with a current ratio of 12.71, but profitability is weak.
- Revenue is concentrated in a single business segment, increasing exposure to sector-specific risks.
- Analyst estimates suggest higher revenue, but this is not yet reflected in the company's financial performance.
- The company's capital expenditures and operating cash flow suggest it is maintaining operations but not growing significantly.
- Risk factors include medium liquidity risk and the need for operational improvements to restore profitability.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Beijing Leadman Biochemistry Co Ltd Market data — financials · 2026-05-26
- Beijing Leadman Biochemistry Co Ltd Market data — analyst estimates · 2026-05-26